Nov 26, 2025 | 3 minute read
Philips has announced the introduction of a new generation of AI-enabled Cardiac MR (CMR) innovations designed to make cardiac MR faster, easier, and more accessible for clinicians and patients. The new AI-powered CMR solutions simplify workflows, expand access to advanced imaging, and deliver diagnostic precision for a wider range of patients — helping clinicians detect and manage heart disease earlier and with greater confidence [1]. The innovations, which will be showcased at RSNA 2025 in Chicago, include:
Combined with Philips’ BlueSeal helium-free MR systems, these solutions offer a more sustainable [7], reliable, and accessible approach to advanced cardiac imaging.

“Cardiac MR is one of the most powerful tools we have to assess the heart, but its complexity and exam length have been a limiting factor until now,” said Ioannis Panagiotelis, PhD, Business leader of MR at Philips. “By integrating AI throughout the workflow, we’re making cardiac MR faster, simpler, and more consistent – giving clinicians time back, improving patient comfort, and expanding access to precision cardiac care.”
By integrating AI throughout the workflow, we’re making cardiac MR faster, simpler, and more consistent – giving clinicians time back, improving patient comfort, and expanding access to precision cardiac care.
AI-driven automation not only addresses staffing shortages by reducing the need for expert operators but also enhances department productivity. Shorter planning times, fewer breath-holds, and reduced motion artifacts cut exam durations and repeat scans, increasing throughput with existing scanners and staff.
Patients benefit from a faster, more comfortable experience, with up to 75% fewer breath-holds with SmartHeart [4] and simplified free-breathing imaging techniques. For technologists, automated workflows minimize manual steps, reducing cognitive load and variability, and allowing more time for patient care.

In addition to improving efficiency and access, Philips’ smart cardiac innovations enable new service lines and referral opportunities, including early detection of heart failure and cardio-oncology monitoring. Quantitative biomarkers such as intramyocardial strain imaging [6] (SENC, MyoStrain) can identify subtle myocardial damage in as little as 10 minutes [6], supporting proactive management of high-risk patients.
By enabling diagnostic-quality imaging for more patients, including those who were previously excluded, Philips is helping health systems deliver better care to more people, bringing the benefits of advanced cardiac MR to more communities around the world.
With this new suite of AI-powered innovations, Philips reaffirms its leadership in cardiac MR and its commitment to transforming the diagnostic pathway through smart, accessible technology. These solutions not only elevate image quality and diagnostic precision but also simplify the MR experience — empowering clinicians to deliver faster, more confident, and more personalized cardiac care. For more information, visit Philips at RSNA 2025 (Chicago, November 30 – December 3).
Sources [1] Improving patient access based on improved workflow with AI powered SmartHeart, CINE Freebreathing and single beat acquisition. Deliver diagnostic precision with Dual AI powered SmartSpeed Precise, Cardiac Motion Correction and CardiacQuant Perfusion.
[2] 510K pending. Not available for sale in the USA. Not yet CE marked, and not yet available for delivery.
[3] Reconstruction technology consisting of a first AI engine applied at the source of signal (Adaptive CS-NET) and a second AI engine applied on the raw complex imaging data (Precise Net).
[4] Compared to Philips SENSE imaging.
[5] Compared to Philips SENSE/ C-SENSE imaging.
[6] Due to using our BlueSeal magnet with helium-free MR operations.
[7] Delivered in partnership with © Myocardial Solutions, Inc. 2021. All rights reserved.
* The opinions and clinical experiences presented herein are specific to the featured topic(s), are not linked to any specific patient and are for information purposes only. The medical experience(s) derived from these topics may not be predictive of all patients. Individual results may vary depending on a variety of patient-specific attributes and related factors. Nothing in this presentation is intended to provide specific medical advice or to take the place of written law or regulations.